Meclizine

The selected prescription meclizine label treats vertigo associated with diseases affecting the vestibular system in adults. Pediatric prescription effectiveness is not established. It does not provide a universal treatment plan for all new dizziness or a diagnosis-specific repositioning protocol.

Selected Dramamine Less Drowsy 25 mg tablets prevent and treat nausea, vomiting and dizziness associated with motion sickness. Its age-12-and-older Drug Facts directions do not establish pediatric approval for the prescription vertigo indication. Other Dramamine products can contain different ingredients.

Selected prescription conventional tablets must be swallowed whole. Selected prescription 25 mg chewable tablets must be chewed or completely crushed before swallowing; do not swallow them whole. OTC tablet instructions depend on the specific dispensed product; do not assume every 25 mg tablet is chewable.

Renal and hepatic pharmacokinetics have not been evaluated. Use cautiously because impaired metabolism or drug / metabolite accumulation may increase exposure. Older-patient dose selection generally starts toward the lower end after reviewing comorbidity and other medicines. The selected label supplies no verified creatinine-clearance, Child-Pugh or weight-based adjustment table.

Prescription dosing follows clinical response; the label does not establish a universal fixed duration or a missed-dose doubling instruction. Follow the clinician’s schedule and reassess benefit versus sedation. OTC first-dose timing applies to motion sickness; persistent or unexplained dizziness needs clinical assessment rather than an assumed vestibular diagnosis.

The selected prescription label contraindicates hypersensitivity to meclizine or its inactive ingredients. Asthma, glaucoma and enlarged prostate are labeled cautions rather than formal prescription contraindications. OTC below-12 use requires a doctor’s direction; do not infer an OTC pediatric dose.

Neither selected Rx nor OTC meclizine labeling has a boxed warning. Drowsiness, interactions and serious allergy still matter.

The prescription label reports drowsiness, dry mouth, headache, fatigue, vomiting and anaphylactic reactions; blurred vision has occurred rarely. Voluntary reports do not supply a reliable overall frequency or prove every reported event is caused by the drug. The OTC label emphasizes drowsiness without a comparative nonsedating claim.

Alcohol and other CNS depressants may increase CNS depression. Review sedatives, tranquilizers, sleep medicines and other sedating treatments before combining; avoid alcohol and assess impairment. Do not assume an OTC product is interaction-free.

In-vitro evidence identifies CYP2D6 metabolism, creating a potential interaction with CYP2D6 inhibitors. Monitor clinical effect and adverse reactions; the label supplies no validated universal percentage adjustment or numerical dose cap for every inhibitor.

CYP2D6 metabolizer variation may contribute to different exposures; monitor response and adverse effects instead of inventing a genotype dosing algorithm. Check active ingredients in motion-sickness, allergy and cold products to avoid inadvertent duplicate meclizine or additive sedation.

Epidemiologic pregnancy studies generally have not identified increased major-birth-defect risk, but animal studies reported malformations at clinically relevant exposure comparisons. Individualize the treatment decision. Human milk transfer, infant effects and milk-production data are absent; consider breastfeeding benefits and maternal need. OTC labeling advises asking a doctor before pregnancy or breastfeeding use.

Prescription pediatric safety / effectiveness are not established. Selected OTC motion-sickness directions allow age 12 or older; below 12 requires doctor direction. Older patients need cautious lower-range dose selection and attention to organ function, other sedating medicines and impairment.

Renal / hepatic impairment has not been studied pharmacokinetically; cautious use is recommended because exposure or accumulation may increase. Genetic CYP2D6 polymorphism may alter exposure. No numerical renal, liver or genotype adjustment is established in the selected Rx label.

Meclizine is a histamine H1 receptor antagonist; the precise therapeutic mechanism is unknown but is presumed to involve H1 antagonism. Potential anticholinergic action contributes to the cautions. It is not a treatment for every underlying cause of dizziness.

Published tablet data summarized in the label show median peak concentration at 3 hours (range 1.5–6 hours) and a plasma half-life around 5–6 hours. Human distribution characteristics are unknown. In-vitro hepatic studies identify CYP2D6 as the dominant metabolic enzyme. These observations do not replace the separate OTC once-daily directions or the individualized Rx divided-dose plan.

Review the cause / indication, dose, sedation, driving demands, asthma / breathing disease, glaucoma, prostate / urinary symptoms, organ function and concomitant drugs. Monitor clinical effect and adverse reactions when CYP2D6 inhibition or metabolizer variability may matter. Reassess persistent unexplained dizziness; no routine serum-meclizine test or universal monitoring interval is specified.

Avoid alcohol, follow whole-versus-chewable instructions and do not drive until the effect is known. For OTC motion sickness take the first dose 30–60 minutes before activity, follow the once-daily directions and obtain doctor advice for children below 12, pregnancy or breastfeeding. Keep medicines away from children and seek urgent help for serious allergy.

OTC Drug Facts directs immediate medical help or Poison Control at 1-800-222-1222 for overdose. Do not compensate an uncertain dose by guessing or doubling; contact the clinician / pharmacist for instructions. Serious allergic or neurologic impairment requires urgent assessment. The selected sources provide no home reversal or decontamination protocol.

Product

Rising meclizine hydrochloride 25 mg conventional tablet

Route

Oral; prescription

Appearance

Oval two-layer yellow / white; 49 and L

Example package

100 tablets · NDC 16571-661-01

Selected Rx conventional tablets: 12.5, 25 and 50 mg; selected 25 mg chewable: pink round, M 25 on one side and break line on the other, NDC 16571-663-01 (100). Selected OTC Dramamine Less Drowsy tablets contain 25 mg meclizine HCl each. Other brand names, chewable variants or formulations require their own label; the Rx strength is hydrochloride, not an instruction to dose in free-base units.

Selected prescription tablets: 20–25°C, dispensed in a tight, light-resistant container. Selected OTC tablets: 20–25°C. Follow the actual package and expiry; no universal after-opening discard interval is supplied. Store out of children’s reach.